New York, January 09, 2014 -- Moody's Investors Service ("Moody's") commented on Teva Pharmaceutical Industries Ltd.'s ("Teva") announcement that Erez Vigodman will become President and CEO effective February 11, 2014. The selection of Vigodman -- who has been on Teva's board of directors since 2009 -- is credit positive as it reduces the risk that there will be a significant departure from Teva's previously-stated strategy.There is no change to Teva's A3 rating or the negative outlook. Please go to www.moodys.com for our full issuer comment.
Vollständigen Artikel bei Moodys lesen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.